The Future of Treatment for Patients With Medullary Thyroid Cancer
August 15, 2017 – Katie Kosko
A Safety 'NET'
August 12, 2017 – Debu Tripathy, MD
Making Strides in Rare Cancers
August 13, 2017 – Mike Hennessy, Sr.
Comparing Male and Female Breast Cancer
August 14, 2017 – CHARLES L. SHAPIRO, M.D.
One Longtime NET Survivor's Quest to Educate Patients
August 10, 2017 – Arlene Weintraub
A Revolution in the Treatment of Neuroendocrine Tumors
August 09, 2017 – Arlene Weintraub
Angel in the Air for Patients With Cancer
August 09, 2017 – Katie Kosko
New Therapies Bring Hope to Rare Cancer Types
August 04, 2017 – Dara Chadwick
Immunotherapy Treatment Advances in Anal Cancer
August 03, 2017 – Meeri Kim
Hitting a Target in Gastrointestinal Stromal Tumors
August 02, 2017 – Erik Ness
Understanding Retroperitoneal Sarcoma
August 01, 2017 – WILLIAM TSENG, M.D.
Rare Cancer Reality
July 31, 2017 – Katie Kosko
On a Mission: Mesothelioma Survivor Fights for Awareness, Understanding and Hope
April 05, 2017 – Lauren M. Green
The Future of Treatment for Patients With Medullary Thyroid Cancer
August 15, 2017 – Katie Kosko
A Safety 'NET'
August 12, 2017 – Debu Tripathy, MD
Currently Viewing
Making Strides in Rare Cancers
August 13, 2017 – Mike Hennessy, Sr.
One Longtime NET Survivor's Quest to Educate Patients
August 10, 2017 – Arlene Weintraub
A Revolution in the Treatment of Neuroendocrine Tumors
August 09, 2017 – Arlene Weintraub
Angel in the Air for Patients With Cancer
August 09, 2017 – Katie Kosko
New Therapies Bring Hope to Rare Cancer Types
August 04, 2017 – Dara Chadwick
Immunotherapy Treatment Advances in Anal Cancer
August 03, 2017 – Meeri Kim
Hitting a Target in Gastrointestinal Stromal Tumors
August 02, 2017 – Erik Ness
Understanding Retroperitoneal Sarcoma
August 01, 2017 – WILLIAM TSENG, M.D.
Rare Cancer Reality
July 31, 2017 – Katie Kosko
On a Mission: Mesothelioma Survivor Fights for Awareness, Understanding and Hope
April 05, 2017 – Lauren M. Green

Making Strides in Rare Cancers

WHAT IS A RARE CANCER? The American Cancer Society (ACS) defines it as fewer than six cases per 100,000 people each year. And, according to the ACS, that means this year there will be an estimated 208,000 new cases of rare cancers in the United States.
BY Mike Hennessy, Sr.
PUBLISHED August 13, 2017
WHAT IS A RARE CANCER? The American Cancer Society (ACS) defines it as fewer than six cases per 100,000 people each year. And, according to the ACS, that means this year there will be an estimated 208,000 new cases of rare cancers in the United States.

So, what does this mean for patients? Is there new, cutting-edge research available to help treat them? In this special issue of CURE®, our cover story examines the progress being made with immunotherapy in anal cancer. Although rare, the number of cases of the disease have been on the rise in the U.S. over the past several decades. Most recently a multicenter phase 2 trial investigating Opdivo (nivolumab) showed great promise in patients with metastatic anal cancer, where there is no standard of care. We spoke with the lead author on this study, who explains the current advances and what lies ahead in treatment.

This month, we also hear from a mesothelioma survivor — given just 15 months to live — who, 11 years later, is making it her personal mission to raise awareness of the disease and fight for understanding for those who suffer from it. In addition, patients and survivors will learn about the differences in men with breast cancer compared with women as explained by a leading oncology expert. We also explore why gallbladder cancer rates have been decreasing in men, but not in women.

Also inside this issue, we spotlight a group that is taking advocacy work to new heights — 45,000 feet up in the air! Corporate Angel Network (CAN) is helping patients with cancer and survivors gain access to top-rated cancer centers for treatment that they might not otherwise have received close to their hometown. CAN offers free flights to and from the centers throughout the U.S. thanks to the support they receive from corporations that provide space on their corporate jets. We hope you find this special issue insightful and resourceful in learning about what the future holds for patients with rare cancers.

As always, thank you for reading.

MIKE HENNESSY, SR. 
Chairman and CEO 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In